Sara E Meyer

11PUBLICATIONS
34CO-AUTHORS
Molecular targetsAutoimmunityMedical infection agents (incl. prions)Language documentation and descriptionHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 15, 2026
P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

|Aug 20, 2025
TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells.

Michael E Lawler, Jennifer S Romer-Seibert, Michael S Bowman

|Nov 23, 2024
miR-196b-Oct1/2 axis regulates DNMT3A-mutant AML pathogenesis.

Michael E Lawler, Melanie L Goetz, Jennifer S Romer-Seibert

|Mar 23, 2023
Context is key for FLT3-ITD.

Sara E Meyer

|Aug 09, 2022
miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.

Holly A Gamlen, Jennifer S Romer-Seibert, Michael E Lawler

|Dec 02, 2021
KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.

Fangxue Yan, Jinyang Li, Jelena Milosevic

Pageof 2

Frequent Collaborators

3 joint publications

Melanie L Goetz

3 joint publications

Michael E Lawler

3 joint publications

Robert L Bowman

2 joint publications

Amanda M Versace